On July 22, 2025, HC Wainwright & Co. released an update regarding SAB Biotherapeutics (SABS, Financial), maintaining their "Buy" rating on the stock. This update was provided by analyst Emily Bodnar, who continues to support a positive outlook for the company.
While the rating remains unchanged, there has been an adjustment in the price target for SAB Biotherapeutics (SABS, Financial). The previous price target was set at USD 10.00, but it has now been lowered to USD 9.00. This represents a 10% decrease from the prior target.
Investors observing SAB Biotherapeutics (SABS, Financial) should note this price target adjustment as part of their broader investment decisions. Despite the target reduction, the maintained "Buy" rating indicates continued analyst confidence in the company's market performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for SAB Biotherapeutics Inc (SABS, Financial) is $12.25 with a high estimate of $20.00 and a low estimate of $7.00. The average target implies an upside of 353.70% from the current price of $2.70. More detailed estimate data can be found on the SAB Biotherapeutics Inc (SABS) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, SAB Biotherapeutics Inc's (SABS, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
